DOCSLIB.ORG

Nih Guidelines for Research Involving Recombinant Or Synthetic Nucleic Acid Molecules (Nih Guidelines)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nih Guidelines for Research Involving Recombinant Or Synthetic Nucleic Acid Molecules (Nih Guidelines) NIH GUIDELINES FOR RESEARCH INVOLVING RECOMBINANT OR SYNTHETIC NUCLEIC ACID MOLECULES (NIH GUIDELINES) APRIL 2019 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health ************************************************************************************************************************ Visit the NIH OSP Web site at: https://osp.od.nih.gov NIH OFFICE OF SCIENCE POLICY CONTACT INFORMATION: Office of Science Policy, National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, MD 20892-7985 (20817 for non-USPS mail), (301) 496-9838; (301) 496-9839 (fax). For inquiries, information requests, and report submissions: [email protected] These NIH Guidelines shall supersede all earlier versions until further notice. ************************************************************************************************************************ Page 2 - NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (April 2019) FEDERAL REGISTER NOTICES Effective June 24, 1994, Published in Federal Register, July 5, 1994 (59 FR 34472) Amendment Effective July 28, 1994, Federal Register, August 5, 1994 (59 FR 40170) Amendment Effective April 17, 1995, Federal Register, April 27, 1995 (60 FR 20726) Amendment Effective December 14, 1995, Federal Register, January 19, 1996 (61 FR 1482) Amendment Effective March 1, 1996, Federal Register, March 12, 1996 (61 FR 10004) Amendment Effective January 23, 1997, Federal Register, January 31, 1997 (62 FR 4782) Amendment Effective September 30, 1997, Federal Register, October 14, 1997 (62 FR 53335) Amendment Effective October 20, 1997, Federal Register, October 29, 1997 (62 FR 56196) Amendment Effective October 22, 1997, Federal Register, October 31, 1997 (62 FR 59032) Amendment Effective February 4, 1998, Federal Register, February 17, 1998 (63 FR 8052) Amendment Effective April 30, 1998, Federal Register, May 11, 1998 (63 FR 26018) Amendment Effective April 29, 1999, Federal Register, May 11, 1999 (64 FR 25361) Amendment Effective October 2, 2000, Federal Register, October 10, 2000 (65 FR 60328) Amendment Effective December 28, 2000, Federal Register, January 5, 2001 (66 FR 1146) Amendment Effective December 11, 2001, Federal Register, December 11, 2001 (66 FR 64051) Amendment Effective December 19, 2001, Federal Register, November 19, 2001 (66 FR 57970) Amendment Effective January 10, 2002, Federal Register, December 11, 2001 (66 FR 64052) Amendment Effective January 24, 2002, Federal Register, November 19, 2001 (66 FR 57970) Amendment Effective September 22, 2009, Federal Register, September 22, 2009 (74 FR 48275) Amendment Effective January 19, 2011, Federal Register, January 19, 2011 (76 FR 3150) Amendment Effective May 12, 2011, Federal Register, May 12, 2011 (76 FR 27653) Amendment Effective October 11, 2011, Federal Register, October 11, 2011 (76 FR 62816) Amendment Effective February 21, 2013, Federal Register, February 21, 2013 (78 FR 12074) Amendment Effective March 5, 2013, Federal Register, September 5, 2012 (77 FR 54584) Amendment Effective November 6, 2013, Federal Register, November 6, 2013 (78 FR 66751) Amendment Effective April 27, 2016, Federal Register, March 22, 2016 (81 FR 15315) Amendment Effective April 15, 2016, Federal Register, April 15, 2016 (81 FR 22286) Amendment Effective April 25, 2019, Federal Register, April 26, 2019 (84 FR 17858) Page 3 - NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (April 2019) TABLE OF CONTENTS NIH Office of Science Policy Contact Information: ................................................................................. 1 SECTION I. SCOPE OF THE NIH GUIDELINES ............................................................... 10 Section I-A. Purpose ........................................................................................................... 10 Section I-B. Definition of Recombinant and Synthetic Nucleic Acid Molecules ................. 10 Section I-C. General Applicability ....................................................................................... 10 Section I-D. Compliance with the NIH Guidelines .............................................................. 11 Section I-E. General Definitions ......................................................................................... 11 SECTION II. SAFETY CONSIDERATIONS ........................................................................ 13 Section II-A. Risk Assessment ............................................................................................ 13 Section II-A-1. Risk Groups .................................................................................................... 13 Section II-A-2. Criteria for Risk Groups .................................................................................. 13 Section II-A-3. Comprehensive Risk Assessment .................................................................. 13 Section II-B. Containment .................................................................................................... 14 SECTION III. EXPERIMENTS COVERED BY THE NIH GUIDELINES .............................. 17 Section III-A. Experiments that Require NIH Director Approval and Institutional Biosafety Committee Approval Before Initiation (See Section IV-C-1-b-(1), Major Actions). .......................................................................................................... 17 Section III-A-1. Major Actions under the NIH Guidelines ........................................................ 17 Section III-B. Experiments That Require NIH OSP and Institutional Biosafety Committee Approval Before Initiation ................................................................................ 17 Section III-B-1. Experiments Involving the Cloning of Toxin Molecules with LD50 of Less than 100 Nanograms per Kilogram Body Weight ................................................... 18 Section III-B-2. Experiments that have been Approved (under Section III-A-1-a) as Major Actions under the NIH Guidelines................................................................... 18 Section III-C. Experiments Involving Human Gene Transfer that Require Institutional Biosafety Committee Approval Prior to Initiation ............................................ 18 Section III-C-1. Experiments Involving the Deliberate Transfer of Recombinant or Synthetic Nucleic Acid Molecules, or DNA or RNA Derived from Recombinant or Synthetic Nucleic Acid Molecules, into One or More Human Research Participants ..................................................................................................... 18 Section III-D. Experiments that Require Institutional Biosafety Committee Approval Before Initiation ........................................................................................................... 19 Section III-D-1. Experiments Using Risk Group 2, Risk Group 3, Risk Group 4, or Restricted Agents as Host-Vector Systems (See Section II-A, Risk Assessment).......... 19 Section III-D-2. Experiments in Which DNA From Risk Group 2, Risk Group 3, Risk Group 4, or Restricted Agents is Cloned into Nonpathogenic Prokaryotic or Lower Eukaryotic Host-Vector Systems .................................................................... 19 Section III-D-3. Experiments Involving the Use of Infectious DNA or RNA Viruses or Defective DNA or RNA Viruses in the Presence of Helper Virus in Tissue Culture Systems .......................................................................................................... 20 Section III-D-4. Experiments Involving Whole Animals ........................................................... 20 Section III-D-5. Experiments Involving Whole Plants .............................................................. 21 Section III-D-6. Experiments Involving More than 10 Liters of Culture .................................... 22 Section III-D-7. Experiments Involving Influenza Viruses ........................................................ 22 Section III-E. Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation ............................................................................ 23 Section III-E-1. Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus .............................................................................................. 23 Section III-E-2. Experiments Involving Whole Plants .............................................................. 24 Section III-E-3. Experiments Involving Transgenic Rodents ................................................... 24 Section III-F. Exempt Experiments ....................................................................................... 25 Page 4 - NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (April 2019) SECTION IV. ROLES AND RESPONSIBILITIES ................................................................ 26 Section IV-A. Policy .............................................................................................................. 26 Section IV-B. Responsibilities of the Institution .................................................................... 26 Section IV-B-1. General Information ........................................................................................ 26 Section IV-B-2. Institutional Biosafety Committee (IBC) .........................................................
Load more

Recommended publications
  • Dekalb Avenue Traffic Calming and Bicycle Lane Project
    DeKalb Avenue Traffic Calming and Bicycle Lane Project NYC Department of Transportation Presentation to Brooklyn Office of Alternate Modes Community Boards 2 & 3 March 2008 Why are we here? • Bicycle Fatality & Serious Injury Study – Improve Safety • Mayor’s PlaNYC – A Greener Transportation Network • 1997 Bicycle Master Plan NYC DOT Bicycle Program • 200 Mile, 3 Year Bicycle Route Commitment • Targeting Areas of High Demand & Key Connections • Design Approach: 1. Study Best Practices 2. Develop Innovative Designs for Constrained NYC Environment 3. “Complete Streets” Design Philosophy Neighborhood-Wide Bicycle Network Implementation Timeline Tompkins & Throop Aves 1997, 2003 DeKalb Ave (west of Cumberland) 2004 Willoughby Ave April 2007 Carlton Ave & Cumberland St May 2007 Central & Evergreen Aves (Bushwick) June 2007 Bedford Ave October 2007 DeKalb Ave (2.6 miles) May 2008 Franklin Ave August 2008 Commuter Corridor • Bus Commutes to Downtown Brooklyn & Subway • DeKalb is a Key Bus Route – 9th busiest in Brooklyn, 23rd busiest in NYC • B38 running at or near capacity – 2.6% increase in ridership from 2005-2006 (compared to .6% increase in Brooklyn and citywide) Bicycle Demand 12-hour* Bicycle Counts on DeKalb and Willoughby Avenues Cross-street Cross-street Street Cyclists** 1 2 Willoughby Tompkins (97) Marcy Ave Ave Ave 250 Willoughby (163) Clermont Ave Adelphi St Ave 410 Tompkins (138) DeKalb Ave Marcy Ave Ave 350 (132) DeKalb Ave Bedford Ave Skillman St 330 Washington (97) DeKalb Ave Hall St Ave 250 (263) DeKalb Ave Clermont Ave Adelphi
    [Show full text]
  • The Clinical Features of Smallpox
    CHAPTER 1 THE CLINICAL FEATURES OF SMALLPOX Contents Page Introduction 2 Varieties of smallpox 3 The classification of clinical types of variola major 4 Ordinary-type smallpox 5 The incubation period 5 Symptoms of the pre-eruptive stage 5 The eruptive stage 19 Clinical course 22 Grades of severity 22 Modified-type smallpox 22 Variola sine eruptione 27 Subclinical infection with variola major virus 30 Evidence from viral isolations 30 Evidence from serological studies 30 Flat-type smallpox 31 The rash 31 Clinical course 32 Haemorrhagic-type smallpox 32 General features 32 Early haemorrhagic-type smallpox 37 Late haemorrhagic-type smallpox 38 Variola minor 38 Clinical course 38 Variola sine eruptione and subclinical infection 40 Smallpox acquired by unusual routes of infection 40 Inoculation variola and variolation 40 Congenital smallpox 42 Effects of vaccination on the clinical course of smallpox 42 Effects of vaccination on toxaemia 43 Effects of vaccination on the number of lesions 43 Effects of vaccination on the character and evolution of the rash 43 Effects of vaccination in variola minor 44 Laboratory findings 44 Virological observations 44 Serological observations 45 Haematological observations 46 1 2 SMALLPOX AND ITS ERADICATION Page Complications 47 The skin 47 Ocular system 47 Joints and bones 47 Respiratory system 48 Gastrointestinal system 48 Genitourinary system 49 Central nervous system 49 Sequelae 49 Pockmarks 49 Blindness 50 Limb deformities 50 Prognosis of variola major 50 Calculation of case-fatality rates 50 Effects
    [Show full text]
  • Too Cool—Families Catch the Cool!
    2010 SPRING Cool Culture® provides 50,000 underserved families with free, unlimited sponsored by JAQUELINE KENNEDY access to ONASSIS 90 cultural institutionsRESEVOIR - so that parents can provide their children withCENTRAL PARK 80 Hanson Place, Suite 604, Brooklyn, NY 11217 www.coolculture.org educational experiences that will help them succeed in school and life. CENTRAL PARK HARLEM MEER Malky, Simcha, Stanley and Avi Mayerfeld. Fi e tzpa t trick t . Vaness e a Griffi v th and Ys Y abe l Fitzpat FIFTH AVENUE d rick. n a o FIFTH AVENUE i g r e S , a n i t n e g r A Isabella, Sophia and Ethel Zaldaña 108TH ST 107TH ST 106TH ST 103RD ST 105TH ST 102ND ST 104TH ST 101ST ST 100TH ST 99TH ST 98TH ST 97TH ST 96TH ST 95TH ST 94TH ST 93RD ST 92ND ST 91ST ST 90TH ST 89TH ST 88TH ST 87TH ST 86TH ST 85TH ST 84TH ST 83RD ST 82ND ST 81ST ST Felicia and Omaria Williams F e l ic ia a nd he t C C O o o m o a h ri W o To ol— illiams atc l! Families C The Cool Culture community couldn't choose just one. “I really liked came together to Catch the Cool on making stuff and meeting my friend and June 8th at the Museum Mile getting a poster by (artist) Michael Albert,” she said. The siblings – along with Festival! Thousands painted, drew, their sister Ysabel (one), mom Yvette and aunt danced and partied on Fifth Avenue from Vanessa Griffith– participated in art activities 105th Street to 82nd Street, dropping in that included crafting monkey ears at The museums along the way.
    [Show full text]
  • Volume 2: Main Report SCOTTISH PARLIAMENT – SESSION 2
    EDINBURGH TRAM NETWORK EDINBURGH TRAM (LINE TWO) BILL Environmental Statement: Volume 2: Main Report SCOTTISH PARLIAMENT – SESSION 2 PREFACE The Edinburgh Tram Line 2 Environmental Statement is published in five volumes: • Volume 1 Non-Technical Summary • Volume 2 Environmental Statement: Main Report • Volume 3 Figures • Volume 4 Appendices to Main Report • Volume 5 Protected Species Report (Confidential) This document is Volume 2. Table of Contents VOLUME 2 ENVIRONMENTAL STATEMENT: MAIN REPORT ABBREVIATIONS 1 INTRODUCTION 1.1 Background 1-1 1.2 Tram Line 2 and the Tram Network 1-1 1.3 The Environmental Impact Assessment of Tram Line 2 1-1 1.4 The EIA Process 1-1 1.5 Relationship Between Tram Line 1 and Tram Line 2 1-2 1.6 Authors 1-2 1.7 Structure of ES 1-3 2 THE PROPOSED SCHEME 2.1 Introduction 2-1 2.2 The Need for the Scheme 2-1 2.3 Scheme Alternatives 2-2 2.4 Scheme Description 2-4 2.5 Tram Line 2 Infrastructure 2-7 2.6 The Construction Phase 2-11 2.7 Operation of Tram Line 2 2-14 3 APPROACH TO THE EIA 3.1 Introduction 3-1 3.2 Parliamentary Requirements and the EIA Regulations 3-1 3.3 The EIA Process 3-1 3.4 Approach to the Assessment of Impacts 3-2 3.5 Uncertainty, Assumptions and Limitations 3-4 3.6 Scope of the Environmental Statement and Consultation 3-6 4 POLICY CONTEXT 4.1 Introduction 4-1 4.2 Methods 4-1 4.3 National and Regional Planning Guidance 4-3 4.4 Planning Policies of The Local Authority 4-6 4.5 Summary 4-13 5 TRAFFIC AND TRANSPORT 5.1 Introduction 5-1 5.2 Methods 5-1 5.3 Baseline Situation 5-4 5.4 Construction Effects
    [Show full text]
  • August 8.2019 Andy Byford President MTA New York City Transit 2
    VELMANETTE MONTGOMERY MAIORITY SECRETARY 25TH SENATE DISTRIa CHAIR 44 &, CHIDREN C FWILIES ALBANY COMMITtEES: OFFICE -. ROOM 015 ACRICUTURE LEGISLATIVE OFRCE BUILDING ‘‘ ‘A ALaY NEWYORK 12237 ‘ cWMEVICrIMS. CRIME C C0RREa:oN PHONE- (SI RI 4SSJ4S I —j_tiai_ EDUCAT OS FAX 151RI420-0853 DISTRICT OFFiCE THE SE NATE F:NASCE IUTHRD AVENUE, SUIt 207 HEALTH BROOKLYN NEWYORK 11217 STATE OF NEW YORK PHONE 171811,43-6140 FAX 7 RI 237-4137 A L BA NY E-MAIL MONTCDMENYSENATECOV WEBSITE, MONTGOMERY NYSENATE CDV August 8.2019 Andy Byford President MTA New York City Transit 2 Broadway New York, NY 10004 Craig Cipriano Executive Vice President MTA New York City Transit Department of Buses 2 Broadway New York, NY 10004 Re: B38 and B54 Bus Service Dear President Byford and Executive Vice President Cipriano: I join my colleagues, constituents and communih’ stakeholders in opposition to the proposed reduction in senice along the B38 and the B54 bus routes. Thousands of Brooklyn residents rely on these bus routes to get to and from work, school and medical appointments. Often these buses connect riders to the subway system to travel into Manhattan and points beyond. Any reduction in service resulting in greater wait times and overcrowded buses is an assault on the quality of life to people who need this bus service and do not have other transportation options. The MTA’s Fast Forward Plan includes the evaluation and “redesign” of the New York City bus network. The Brooklyn Bus Redesign has not yet taken place. Therefore. these changes are simply premature. Why are we redesigning services when an evaluation of the Brooklyn bus network has yet to be initiated? I strongly oppose any change in service until the roots of the problem have been appropriately studied and identified.
    [Show full text]
  • Fatigue Tests of Curved Plate Girder Assemblies
    TE 662 .A3 )rt No. FHWA-RD-79-133 no. FF T ' Rl 79 FATIGUE OF CURVED STEEL BRIDGE ELEMENTS Fatigue Tests of Curved Plate Girder Assemblies April 1980 Interim Report Diaphragm (typ) Girder 2 DEPARTMENT OF TRANSPORTATION JUL 1 1930 LIBRARY Girder Document is available to the public through the National Technical Information Service, Springfield, Virginia 22161 Prepared for FEDERAL HIGHWAY ADMINISTRATION SPATES O* Offices of Research & Development Structures & Applied Mechanics Division Washington, D.C. 20590 FOREWORD Horizontally curved steel plate and box girders are being used more frequently for highway structures, sometimes because of increased economy, and because of their esthetic appearance. The design of curved girders differs from that of straight gir- ders in that torsional effects, including nonuniform torsion, must be considered. The resulting use of lateral bracing between curved plate girders and internal bracing and stiffen- ing of curved box girders gives rise to complicated states of stress and to details which can be sensitive to repetitive loads. This situation prompted the FHWA to sponsor this research, the primary objective of which is to establish fatigue design guide- lines for curved girder highway bridges in the form of simplified equations or charts. This report is one in a series of eight on the results of the research and is being distributed to the Washington and field offices of the Federal Highway Administration, State highway agencies, and interested researchers. Charles F. Sc^e^Tey Director, Office of Research Federal Highway Administration NOTICE This document is disseminated under the sponsorship of the Department of Transportation in the interest of information exchange.
    [Show full text]
  • Oklahoma Disease Reporting Manual
    Oklahoma Disease Reporting Manual List of Contributors Acute Disease Service Lauri Smithee, Chief Laurence Burnsed Anthony Lee Becky Coffman Renee Powell Amy Hill Jolianne Stone Christie McDonald Jeannie Williams HIV/STD Service Jan Fox, Chief Kristen Eberly Terrainia Harris Debbie Purton Janet Wilson Office of the State Epidemiologist Kristy Bradley, State Epidemiologist Public Health Laboratory Garry McKee, Chief Robin Botchlet John Murray Steve Johnson Table of Contents Contact Information Acronyms and Jargon Defined Purpose and Use of Disease Reporting Manual Oklahoma Disease Reporting Statutes and Rules Oklahoma Statute Title 63: Public Health and Safety Article 1: Administration Article 5: Prevention and Control of Disease Oklahoma Administrative Code Title 310: Oklahoma State Department of Health Chapter 515: Communicable Disease and Injury Reporting Chapter 555: Notification of Communicable Disease Risk Exposure Changes to the Communicable Disease and Injury Reporting Rules To Which State Should You Report a Case? Public Health Investigation and Disease Detection of Oklahoma (PHIDDO) Public Health Laboratory Oklahoma State Department of Health Laboratory Services Electronic Public Health Laboratory Requisition Disease Reporting Guidelines Quick Reference List of Reportable Infectious Diseases by Service Human Immunodeficiency Virus (HIV) Infection and Acquired Immunodeficiency Syndrome (AIDS) Anthrax Arboviral Infection Bioterrorism – Suspected Disease Botulism Brucellosis Campylobacteriosis CD4 Cell Count < 500 Chlamydia trachomatis,
    [Show full text]
  • Weirfield Development Package Table of Contents I
    L WEIRFIELD DEVELOPMENT PACKAGE TABLE OF CONTENTS I. EXECUTIVE SUMMARY II. THE NEIGHBORHOOD III. DUE DILIGENCE FOR MORE INFORMATION, PLEASE CONTACT DJ JOHNSTON Partner, Senior Managing Director 646 933 2619 [email protected] WILLIAM CHENG L Director 646 933 2623 [email protected] MICHAEL MURPHY Senior Associate 646 933 2638 [email protected] BEN RECHLER Associate 646 933 2657 [email protected] EXECUTIVE SUMMARY THE OPPORTUNITY PROPERTY INFORMATION B6 Real Estate Advisors is pleased to announce that it has of new restaurants, cafes, bars, art galleries, retail stores 389 391 1438 376 378 380 ADDRESS SUMMARY been retained on an exclusive basis to arrange for the sale of and creative work lofts, Bushwick, Brooklyn has emerged WEIRFIELD WEIRFIELD HANCOCK WEIRFIELD WERFIELD WEIRFIELD this extensive residential development assemblage located on as one of the fastest growing and most sought after real the Halsey L train station in Bushwick, Brooklyn. The portfolio estate markets in all of New York City. From an investment Block / Lot 3400 / 68 3400 / 63 3400 / 35 3407 / 21 3407 / 26 3407 / 27 -- features roughly 78,199 buildable square feet, just steps from perspective, Bushwick presents a rare opportunity to purchase 26.44' x 100' 30.33' x 196' Lot Size 30.54' x 100' 100.4' x 100' 30' x 200.21' 100.37' x 100' -- the L train, with convenient access to Union Square and real estate in a stable yet rapidly appreciating neighborhood at Irreg. Irreg. Williamsburg within 20 minutes. The large scale of this offering, a significant discount as compared to similar neighborhoods Lot SF 3,054 10,040 6,006 10,037 2,153 5,850 37,140 truly uncommon for the Bushwick area, provides developers like Williamsburg and Greenpoint.
    [Show full text]
  • 615 Cross Immunity Experiments in Monkeys Between Variola, Alastrim
    615 CROSS IMMUNITY EXPERIMENTS IN MONKEYS BETWEEN VARIOLA, ALASTRIM AND VACCINIA BY E. S. HORGAN, M.D. AND MANSOUR ALI HASBEB Stack Medical Research Laboratories, Khartoum PART I. VARIOLA AND VACCINIA IN spite of the voluminous literature, much of it of a polemical rather than scientific nature, on the immunity relationships between variola and vaccinia, comparatively little work has been carried out on experimental animals, and the results of different workers are not altogether concordant. Even in the important article by Blaxall (1930) in the System of Bacteriology only a few lines were devoted to a discussion of the existing experimental evidence, and also in the more recent article by Gastinel (1938) this particular problem has been very briefly treated. PRESENT EXPERIMENTAL WORK Opportunity was taken during an outbreak of virulent smallpox in the Gezira cotton-growing area of the Anglo-Egyptian Sudan in 1938 to collect variolous material from different patients, and to inoculate a series of monkeys. TECHNIQUE The contents of the vesicles or pustules were aspirated into capillary tubes, which were immediately packed in ice in a vacuum flask and brought directly to Khartoum, 80 miles from the epidemic zone. The capillary tubes with the pus were ground up in a mortar with distilled water (pH. 7*0), the suspension lightly centrifuged to throw down the powdered glass, and the turbid super- natant fluid pipetted off and stored in the freezing chamber of a refrigerator. Inoculation was made on to the scarified bellies of monkeys (Cercopithecus sebaeus), the amount of inoculum and area varying in different animals, and the subsequent immunity tests were carried out with both vaccinia and variola.
    [Show full text]
  • Neutralization Tests on the Chorio-Allan- Tois with Unabsorbed and Absorbed Immuine Sera
    789 THE VIRUSES OF VARIOLA, VACCINIA, COWPOX AND ECTRO- MELIA.-NEUTRALIZATION TESTS ON THE CHORIO-ALLAN- TOIS WITH UNABSORBED AND ABSORBED IMMUINE SERA. A. W. DOWNIE AND K. McCARTHY. From the Department of Bacteriology, Univer8ity of Liverpool. Received for publication October 30, 1950. IN a previous paper we recorded the results of neutralization tests with the viruses of variola, vaccinia, cowpox and ectromelia and corresponding immune sera (McCarthy and Downie, 1948). Four strains of variola, two strains each of vaccinia and cowpox and one strain each of alastrim and ectromelia viruses were examined. Immune sera from immunized fowls and rabbits and from man were used in neutralization tests made by inoculating serum-virus mixtures on the chorio-allantois of chick embryos or into the skin of rabbits. In the tests on the chorio-allantois, undiluted immune sera prepared against each of the virus strains was tested against a constant amount of virus, and in the rabbit skin constant amounts of sera were tested against varying amounts of cowpox and vaccinia viruses. These cross-neutralization tests showed the close relationship of the strains studied and failed to demonstrate distinct differences among them. In an attempt to disclose such differences we have made an estimate of the neutra- lizing antibody in immune sera by testing five-fold dilutions of the sera against homologous and heterologous viruses. In this extension of the previous work only immune sera prepared in fowls have been studied and all neutralization tests have been made on the chorio-allantois of chick embryos. In addition, we have carried out absorption of immune fowl sera with virus suspensions and tested the absorbed sera for neutralizing power.
    [Show full text]
  • Bushwick Ridgewood
    Neighborhood Map ¯ Suydam and Suydam School, Willoughby School, Willoughby Gardens PS 123 Suydam Street JHS 162 Suydam Street Suydam Street Metropolitan Avenue Suydam Street 3-01 125 114 91 91 92 72 282 285 96 54 Street 54 1702 54 Place 54 969 Avenue Wyckoff 971 1019 1021 1073 1851 1899 887 889 B13 53-99 Hart Street Hart Street Hart Street Ahawith Hart Street Wyckoff Avenue Grandview Irving Avenue Irving Chesed 60-99 Avenue Linden Hill 60-99 54-11 139 134 Cemetery Arnold Avenue 111 314 86 112 134 310 1702 309 B38 Cemetery 54-01 54-30 Cypress Avenue Cypress 1899 3-49 21-17 1627 1629 1679 1681 B38 1729 1733 1849 1851 1547 1549 B38 Nicholas Avenue St. B38 LTD B38 LTD DeKalb Avenue DeKalb Avenue DeKalb Avenue Rene Court DeKalb Avenue Q54 B38 B38 B38 B38 21-20 LTD Q54 LTD DeKalb Av 3-51 Metropolitan Avenue Grover B38 165 156 146 131 129 126 376 359 106 360 360 1801 Cleveland Playground 54-99 337 339 383 385 427 431 499 1801 1849 1851 1899 3-69 21-17 Woodward Avenue Woodward 279 281 Avenue Onderdonk Stockholm Street Stockholm Street Stockholm Street Amory Court Stockholm Street 1 55-01 St. Aloysius Wyckoff Heights Learners and Leaders School, PS 305 Roman Catholic 179 Church 172 Medical Center 381 381 384 166 142 153 122 2 382 1849 1851 1899 335 381 383 423 1701 1799 279 281 B38 Stanhope Street Stanhope Street Stanhope Street Stanhope Street Geraldine A. 55-36 Stanhope Street Ferraro B38 Irving Avenue Irving Campus Grover Cleveland 193 186 0 High School 61-31 1 412 170 188 169 4-20 173 138 4-01 411 411 4 414 414 407 409 4-08 Iglesia de la Fairview Avenue Fairview 363 365 Santa Cruz 413 451 Avenue Cypress 1701 1799 1801 1849 1851 1899 1901 1999 2001 2099 2101 2199 2201 Grandview Avenue Grandview Wyckoff Av Wyckoff St.
    [Show full text]
  • St. Paul's 30Th Annual Auction
    ST. PAUL’S 30TH ANNUAL AUCTION Saturday, December 1, 2018, doors open at 5 p.m. St. Paul’s Parish Hall, 199 Carroll St. Pottery by Art Stewart © 2018 Pottery by Admission $40 per Adult, includes: Fun Silent Auction, Entertaining Live Auction, Appetizers, and Light Supper Tickets going fast! Buy now! contact [email protected] or call 718-625-4126 Click image for more information A once-in-a-lifetime opportunity to tour the Holyland with fellow St. Paulies! Travel to Galilee, Jerusalem, Bethlehem, and Tel Aviv, for one person for 10 days. • Trip from New York Area Gateway • Airport-hotel transfers (includes fuel surcharges and taxes) • Hotel taxes • Accommodations in superior tourist • Touring by Private Motorcoach class hotels • Services of a Professional Tour Escort • All breakfast and dinners • Sightseeing as per itinerary Click image to launch website Harry Potter & the Cursed Child Parts 1 & 2 CALLING ALL MUGGLES! Come be dazzled by the two-part sequel to the Harry Potter phenomenon that took the London stage by storm, written by JK Rowling and Jack Thorne. Harry Potter & the Cursed Child, Parts One and Two - Tickets for 2 on Thursday May 30th & Friday May 31st , 2019 at 7:30pm, Balcony Seats Row H 106 & 107 (center of the last row of the balcony) at the Lyric Theatre, Lyric Theatre, 214 W 43rd St, New York, NY 10036 Sail Breathtaking New York Harbor on a 24-FootSail the KeelboatBreathtaking New York Harbor Join Nancy Webster for a memorable sail for three people on a J-80 keelboat in New York Harbor, passing Ellis Island, the Statue of Liberty, Governor’s Island, and the Red Hook pier.
    [Show full text]